AI tools aid the discovery of super tight-binding antibodies
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
List view / Grid view
An AI strategy developed by US scientists could accelerate the development of new antibody drugs.
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
Swedish researchers unveiled a new cancer protein profile database compiled from artificial intelligence and machine learning.
US scientists have designed a mathematical model that can predict COVID-19 vaccines’ effectiveness over the long term in healthy individuals and those who have cancer or suppressed immune responses.
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
US researchers have discovered that cancer treatments or anthracycline drugs, cause cardiovascular disease by activating a key inflammatory signalling pathway.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
US researchers, using new machine learning techniques have developed a virtual molecular library of “words” that encode commands to kill cancer cells.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…